Table 2.

Characteristics, treatment times, and local responses of the gene-receiving patients

Patient No.	Gender	Age (year)	Histology	Stage	Gene transfer access	rAd-p53		BAI times	Local response	TTP (month)	Survival duration (month)
						Time	Dose (×1012 VP)
1	M	40	Adeno	IIIa	TA	2	2	3	SD	9	12
2	M	56	Squam	IIIb	TA	2	1	2	SD	6	8
3	M	39	Adeno	IIIa	PI	3	2	3	PD	1	2
4	M	51	Large cell	IIIb	PI	2	2	2	PR	10	12
5	M	53	Squam	IIIa	PI/TA	4	3	4	CR	13	12
6	M	71	Adeno	IV	PI & TC	2	2	1	SD	5	9
7	M	80	Adeno	IV	PI	2	1	2	SD	6	7
8	M	48	Adeno	IIIb	PI & LN	2	3	3	PR	7	12
9	F	56	Squam	IV	TA	2	4	4	SD	4	7
10	F	72	Large cell	IV	PI	3	3	2	PD	2	3
11	M	74	Squam	IV	PI	1	1	2	SD	5	6
12	M	61	Adeno Squam	IIIb	PI	4	1	2	PR	7	11
13	F	54	Adeno	IIIa	TA	2	3	3	PR	9	12
14	F	53	Adeno	IV	TA	3	2	3	PR	6	8
15	M	54	Squam	IIIb	TA	4	2	2	CR	13	12
16	M	59	Squam	IIIa	PI	4	2	2	PR	11	12
17	M	79	Squam	IV	TA	2	1	2	PR	7	12
18	M	46	Squam	IIIa	TA	3	2	3	PR	8	12
19	M	68	Squam	IIIa	TA	2	2	1	PR	10	12

M: male; F: female; Adeno: adenocarcinoma; Squam: squamous; TA: transarterial infusion; TC: thoracic cavity; PI: percutaneous injection; LN: lymph nodes; BAI: bronchial arterial infusion; SD: stable disease; PD: progressive disease; PR: partial response; CR: complete response; TTP: time to progression